Analyst Insights 3 ‘Strong Buy’ Stocks to Buy on Weakness Investors are constantly searching for the next big winner. We mean the stocks that are on track to see explosive growth, handsomely rewarding … Maya Sasson, November 8, 2019
Uncategorized Here’s Why Analysts Remain Confident on Catalyst (CPRX) Stock This week turned out to be a nightmare for shareholders of Catalyst Pharmaceuticals (CPRX), as the stock price plummeted over 50%. So what … Ben Mahaney, Editor, May 10, 2019
Analyst InsightsBiotech Stocks Spooked Investors Sent Catalyst (CPRX) Stock Spiraling, But Analysts Remain Confident This week turned out to be a nightmare for shareholders of Catalyst Pharmaceuticals (CPRX), as the stock price plummeted nearly 55%. What’s causing … Smarter Team, May 9, 2019
Analyst InsightsBiotech Stocks Catalyst Pharmaceuticals (CPRX) Stock Receives Upbeat Wall Street Comments Catalyst Pharmaceuticals (CPRX) hosted a conference call yesterday to discuss its commercialization plan for the company’s newly FDA-approved LEMS drug, Firdapse. Catalyst announced … Jason Cohen, December 14, 2018
Biotech Stocks Analyst Predicts Success for Catalyst Pharmaceutical (CPRX ) Stock Following News of Latest FDA Approval Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, … Shanna Fuld, December 3, 2018
Biotech StocksLong IdeasStock News H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks H.C. Smarter Team, November 15, 2018
Analyst InsightsBiotech StocksStock News Catalyst Pharmaceuticals (CPRX): A Biotech Stock This Analyst Is Closely Watching Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing … Jason Cohen, November 13, 2018
Analyst InsightsBiotech StocksStock NewsTop Stories Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert … Jason Cohen, November 8, 2018
Analyst InsightsBiotech StocksStock News Oppenheimer Pounds the Table on Catalyst Pharmaceuticals (CPRX) Ahead of Upcoming FDA Decision Oppenheimer analyst Leland Gershell was out pounding the table on shares of Catalyst Pharmaceuticals (CPRX), reiterating a Buy rating and price target of $6.00, which implies … Carrie Williams, October 17, 2018
Analyst InsightsBiotech StocksStock News Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX) look forward to important regulatory approval decisions this year. Could these catalysts give these small … Jason Cohen, October 10, 2018
